Accelerated Approval, Arava, Factive Are Topics For Early 2003 Committees
Executive Summary
FDA's accelerated approval policies for cancer agents, a review of GeneSoft's Factive, and a safety update for Aventis' rheumatoid arthritis drug Arava are among the topics for advisory committees in early 2003
You may also be interested in...
Iressa User Fee Date Pushed To May; Will Advisory Cmte. Take Second Look?
FDA will take regulatory action on AstraZeneca's Iressa (gefitinib) by May 5
Accelerated Approval Standards Will Be Advisory Committee Topic In March
FDA is planning an advisory committee meeting to discuss the accelerated approval process for oncologic agents
FDA Advisory Committee Line-Up Shrinks With Elimination Of Two Panels
FDA will reduce its total advisory committee count to 30 with the termination of the Pharmacy Compounding and Medical Imaging Drugs Advisory Committees